MCID: VRL007
MIFTS: 53

Viral Encephalitis

Categories: Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Viral Encephalitis

MalaCards integrated aliases for Viral Encephalitis:

Name: Viral Encephalitis 11 14 16 71 75
Epidemic Encephalitis 11 75
Viral Encephalitis Transmitted by Tick 33
Acute Haemorrhagic Encephalitis 33
Viral Haemorrhagic Encephalitis 33
Viral Nonepidemic Encephalitis 33
Acute Idiopathic Encephalitis 33
Mosquito-Borne Encephalitis 33
Subacute Viral Encephalitis 33
Postviral Encephalitis Nos 33
Chronic Viral Encephalitis 33
Nonepidemic Encephalitis 33
Tick-Borne Encephalitis 33
Encephalitis, Arbovirus 43
Arbovirus Encephalitis 71
Endemic Encephalitis 33
Equine Encephalitis 33
Encephalitis Viral 53

Classifications:



External Ids:

Disease Ontology 11 DOID:646
MeSH 43 D004671
NCIt 49 C34576
SNOMED-CT 68 68197003
ICD10 31 A85.8 A86
ICD11 33 956664712
UMLS 71 C0014055 C0243010

Summaries for Viral Encephalitis

Disease Ontology: 11 An encephalitis that involves inflammation of the brain caused by viral infection.

MalaCards based summary: Viral Encephalitis, also known as epidemic encephalitis, is related to herpes simplex encephalitis and japanese encephalitis. An important gene associated with Viral Encephalitis is VCAM1 (Vascular Cell Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Dexamethasone acetate and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and olfactory bulb, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia 75 Viral encephalitis: Viral encephalitis is inflammation of the brain parenchyma, called encephalitis, by a virus. The... more...

Epidemic encephalitis: Encephalitis is inflammation of the brain. The severity can be variable with symptoms including... more...

Related Diseases for Viral Encephalitis

Diseases in the Encephalitis family:

Viral Encephalitis Autoimmune Encephalitis
Chronic Encephalitis Infectious Encephalitis

Diseases related to Viral Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1069)
# Related Disease Score Top Affiliating Genes
1 herpes simplex encephalitis 31.5 UNC93B1 TLR3
2 japanese encephalitis 31.3 TLR3 IFNB1 IFNA1 CD8A CD4
3 tick-borne encephalitis 31.3 TLR3 IFNA1 CXCL10 CD8A CD4
4 herpes simplex 31.2 UNC93B1 TLR3 IFNB1 IFNA1 CD8A
5 radiculopathy 31.1 IL6 IFNA1 CCL2
6 von economo's disease 31.1 LGI1 CNTNAP2 ACE2
7 rabies 31.1 TLR3 MX1 IFNA1 CXCL10
8 crimean-congo hemorrhagic fever 31.0 IL6 IFNB1 IFNA1
9 herpes zoster 30.8 TLR3 IFNA1 CD8A CD4 CCR6
10 vaccinia 30.8 TNF IL6 IFNB1 IFNA1 CXCL10
11 leptospirosis 30.8 TNF IL6 IL1B CCL2
12 q fever 30.8 TNF IL6 IL1B CCL2
13 typhoid fever 30.7 TNF IL6 IL1B CCR6
14 measles 30.7 TLR3 MX1 IL6 IL1B IFNB1 IFNA1
15 hantavirus pulmonary syndrome 30.6 VEGFA IFNB1 CD8A
16 encephalitis 30.6 VCAM1 UNC93B1 TNF TLR3 MX1 LGI1
17 oral candidiasis 30.6 IL6 CD8A CD4 CCR6
18 polyradiculopathy 30.6 LGI1 CNTNAP2 CD4
19 bell's palsy 30.6 TNF TLR3 MBP IL6 CD8A CD4
20 meningitis 30.6 VEGFA TNF IL6 IL1B CCL2
21 thrombocytopenia due to platelet alloimmunization 30.6 CD8A CD4 CCR6
22 thrombocytopenic purpura, autoimmune 30.6 CD8A CD4 CCR6
23 acute retinal necrosis syndrome 30.5 VEGFA TNF IL6 CD8A CD4
24 tularemia 30.5 TNF IL6 IL1B CD8A CD4 CCR6
25 facial paralysis 30.5 TNF MBP IL6 CD8A CD4 ACE2
26 purpura 30.5 TNF IL6 IL1B
27 echinococcosis 30.5 TNF IL6 CD8A
28 zika fever 30.4 TLR3 IFNB1 IFNA1
29 dengue disease 30.4 TNF IL6 IFNB1 IFNA1 CD8A CD4
30 endogenous depression 30.4 TNF IL6 IL1B
31 myositis 30.3 TNF IL6 IL1B IFNA1 CXCL10
32 autoimmune lymphoproliferative syndrome 30.3 TNF CD8A CD4 CCR6
33 intracranial hypertension 30.3 TNF IL6 IL1B
34 apnea, obstructive sleep 30.3 VEGFA TNF IL6 IL1B
35 newcastle disease 30.3 TNF TLR3 IFNB1 IFNA1 CXCL10
36 sleep disorder 30.3 TNF IL6 IL1B
37 neuritis 30.3 VEGFA TNF MBP IL6 IL1B CXCL10
38 bacterial meningitis 30.3 TNF IL1B CCL2
39 yellow fever 30.3 IL6 IL1B IFNB1 CXCL10 CCL2
40 tonsillitis 30.3 TNF TLR3 IL6 IL1B
41 hepatitis c 30.3 TLR3 MX1 IFNB1 IFNA1 CXCL10
42 subacute sclerosing panencephalitis 30.3 TNF TLR3 MX1 MBP IL6 IFNA1
43 pericardial effusion 30.3 VEGFA TNF IL6 CD4 ACE2
44 syphilis 30.3 TNF CD8A CD4 CCR6
45 urticaria 30.3 TNF IL6 IL1B CD4
46 alopecia areata 30.2 TNF IL6 IL1B CXCL10
47 postinfectious encephalitis 30.2 MBP LGI1 CNTNAP2
48 mumps 30.2 TNF TLR3 MX1 IL6 IL1B IFNB1
49 stomatitis 30.2 TNF MX1 IL6 IL1B IFNB1 IFNA1
50 thrombocytopenia 30.2 VEGFA TNF IL6 IL1B IFNB1 IFNA1

Graphical network of the top 20 diseases related to Viral Encephalitis:



Diseases related to Viral Encephalitis

Symptoms & Phenotypes for Viral Encephalitis

GenomeRNAi Phenotypes related to Viral Encephalitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 ACE2 CCL2 CCR6 CD4 CD8A CNTNAP2
2 no effect GR00402-S-2 10.13 CCL2 CCR6 CD4 CXCL10 DBR1 IFNA1

MGI Mouse Phenotypes related to Viral Encephalitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ACE2 CCL2 CCR6 CD4 CXCL10 DBR1
2 nervous system MP:0003631 10.21 CCL2 CCR6 CD4 CD8A CNTNAP2 CXCL10
3 immune system MP:0005387 10.11 ACE2 CCL2 CCR6 CD4 CD8A CXCL10
4 cellular MP:0005384 10.03 ACE2 CCL2 CD4 CD8A CNTNAP2 CXCL10
5 neoplasm MP:0002006 9.95 CCL2 IFNB1 IL1B IL6 TLR3 TNF
6 hematopoietic system MP:0005397 9.91 ACE2 CCL2 CCR6 CD4 CD8A CXCL10
7 mortality/aging MP:0010768 9.53 ACE2 CCL2 CD4 CD8A CXCL10 DBR1

Drugs & Therapeutics for Viral Encephalitis

Drugs for Viral Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
4
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
8
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
9
Dimenhydrinate Approved Phase 4 523-87-5 10660
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
11
Polygeline Experimental Phase 4 66455-30-9
12 Antineoplastic Agents, Hormonal Phase 4
13 Neuroprotective Agents Phase 4
14 Hormones Phase 4
15 Hormone Antagonists Phase 4
16 glucocorticoids Phase 4
17 Anti-Inflammatory Agents Phase 4
18
Methylprednisolone Acetate Phase 4 584547
19 Protective Agents Phase 4
20 Immunologic Factors Phase 4
21 Immunoglobulins Phase 4
22 Antibodies Phase 4
23 Pharmaceutical Solutions Phase 4
24
Aluminum sulfate Approved Phase 1 10043-01-3
25
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
26 Gastrointestinal Agents Phase 1
27 Anti-Ulcer Agents Phase 1
28 Adjuvants, Immunologic Phase 1
29 Antacids Phase 1
30 Iron-Dextran Complex Phase 1
31
Ceftriaxone Approved 73384-59-5 5479530
32
Thiethylperazine Approved, Withdrawn 1420-55-9 5440
33
Metamizole Approved, Investigational, Withdrawn 50567-35-6 3111 522325
34
Granisetron Approved, Investigational 109889-09-0 3510 5284566
35
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
36 Antitubercular Agents
37 Antiemetics
38 Antibiotics, Antitubercular
39 Anti-Bacterial Agents
40 Antipyretics
41 Anti-Infective Agents
42 Antiprotozoal Agents
43 Antiparasitic Agents
44 Antimalarials

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis Unknown status NCT04103684 Phase 4 Methylprednisolone;Dexamethasone
2 Application of a TBE-Vaccine in Obese Persons Unknown status NCT04017052 Phase 4 FSME-IMMUN Vaccine
3 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
4 Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223) Completed NCT00503529 Phase 4
5 Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT03294135 Phase 4
6 TBE (Tick-borne Encephalitis ) Vaccination in Allergic Patients Completed NCT02511535 Phase 4
7 Open-label Phase Iv Study To Investigate The Seropersistence Of Tick-borne Encephalitis (Tbe) Virus Antibodies After The First Booster And The Response To A Second Booster Vaccination With Fsme-immun In Children, Adolescents And Young Adults (Follow-up To Study 700401) Completed NCT00894686 Phase 4
8 Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years Completed NCT00161967 Phase 4
9 A Phase IV, Open-label, Multi-center Follow-up Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
10 Phase 4 Clinical Trial of Cervico-vaginal Immune Responses Following Three Right Deltoid or Right Thigh Intramuscular Immunisations With TicoVac (Tick Borne Encephalitis Virus [TBEV]) Vaccine in Adult Female Participants Completed NCT01710189 Phase 4 TicoVac
11 Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults Completed NCT01582698 Phase 4
12 A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
13 Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination Completed NCT00804219 Phase 4
14 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
15 Primary TBE Vaccination for the Elderly Not yet recruiting NCT04573205 Phase 4 FSME-IMMUN Vaccine
16 Single-blind, Randomized, Phase 3B Study in Children Aged 1 - 11 Years to Investigate the Immunogenicity, Safety and Interchangeability of Two Tick-borne Encephalitis (Tbe) Vaccines Administered According to a Conventional Schedule Completed NCT00840801 Phase 3
17 A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER Completed NCT04648241 Phase 3
18 Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Completed NCT00161863 Phase 3
19 Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses? Completed NCT02318069 Phase 2, Phase 3
20 Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses? Completed NCT01361776 Phase 2, Phase 3
21 Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine Unknown status NCT00890422 Phase 2
22 Characterization of Humoral and Cellular Immunity for Tick-borne Encephalitis (TBE) Vaccination in Allogeneic Blood and Marrow Graft Recipients: a Pilot Study Completed NCT01991067 Phase 2
23 Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Completed NCT00161798 Phase 2
24 Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Completed NCT00161772 Phase 2
25 Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus Completed NCT02654509 Phase 2
26 A Multi-Site Phase 2 Open-Label, Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 in Healthy Adults At Risk for Exposure to Eastern Equine Encephalitis Virus Completed NCT00584805 Phase 2
27 Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection Recruiting NCT02479698 Phase 2
28 Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus Recruiting NCT02466750 Phase 2
29 A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory Terminated NCT01031537 Phase 2
30 Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis Completed NCT00118924 Phase 1
31 A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Virus-Like Particle (VLP) Encephalitis Vaccine, VRC-WEVVLP073-00-VP, in Healthy Adults Completed NCT03879603 Phase 1
32 Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects Completed NCT04131595 Phase 1
33 A Phase I, Randomized, Observer-blind, Placebo Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered Intramuscularly or Intradermally by Electroporation to Healthy Adults Completed NCT01984983 Phase 1
34 Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults Completed NCT01159561 Phase 1
35 A Phase 1 Dose Escalation Study to Assess the Safety and Immunogenicity of a Monovalent Virus-Like Particle (VLP) Venezuelan Equine Encephalitis Vaccine in Healthy Adults Active, not recruiting NCT03776994 Phase 1
36 Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration Withdrawn NCT00109304 Phase 1
37 Management of Patients With Tick-borne Encephalitis and Positive Anti-Lyme Borreliae Antibody Results Unknown status NCT02463942 Doxycycline;Symptomatic therapy
38 Postencephalitic Symptoms After Tick Borne Encephalitis Unknown status NCT00941590
39 Tick-Borne Encephalitis Virus and Lyme Borreliae Causing Coillness, Coinfection, or Just Coincidence. A Prospective Observational Study Completed NCT03958058 Anti-borrelial antibiotic therapy
40 Prevalence of Tick-borne Encephalitis (TBE) in the Pediatric Population Treated at the University Hospitals of Strasbourg (HUS) and Characterization of Confirmed Pediatric Cases Recruiting NCT05607394
41 Antibiotic Therapy for Patients With Tick-borne Encephalitis and Borrelial Antibodies in Serum Recruiting NCT03956446 Doxycycline;Symptomatic therapy
42 The Norwegian Tick Born Encephalitis Study Acute Phase Characteristics and Long-tern Outcomes Recruiting NCT05138055

Search NIH Clinical Center for Viral Encephalitis

Cochrane evidence based reviews: encephalitis, arbovirus

Genetic Tests for Viral Encephalitis

Anatomical Context for Viral Encephalitis

Organs/tissues related to Viral Encephalitis:

MalaCards : Brain, T Cells, Olfactory Bulb, Temporal Lobe, Salivary Gland, Bone Marrow, Kidney

Publications for Viral Encephalitis

Articles related to Viral Encephalitis:

(show top 50) (show all 8835)
# Title Authors PMID Year
1
[Changes and roles of VEGF and VCAM-1 in cerebrospinal fluid of children with viral encephalitis]. 53 62
18554449 2008
2
Immunohistochemical evaluation of mx protein expression in canine encephalitides. 53 62
17099155 2006
3
Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis. 53 62
16764711 2006
4
Expression of the interferon-induced MxA protein in viral encephalitis. 53 62
12787324 2003
5
Antibody responses to Acinetobacter spp. and Pseudomonas aeruginosa in multiple sclerosis: prospects for diagnosis using the myelin-acinetobacter-neurofilament antibody index. 53 62
11687461 2001
6
Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. 53 62
10465150 1999
7
Structured Imaging Approach for Viral Encephalitis. 62
36404046 2023
8
Methods to Study West Nile Virus Infection and the Virus-Induced Inflammation in the Brain in a Murine Model. 62
36331764 2023
9
Vaccine uptake in 20 countries in Europe 2020: Focus on tick-borne encephalitis (TBE). 62
36410164 2023
10
Continued Circulation of Tick-Borne Encephalitis Virus Variants and Detection of Novel Transmission Foci, the Netherlands. 62
36288572 2022
11
Crystal structure and cap binding analysis of the methyltransferase of langat virus. 62
36347437 2022
12
Decontamination efficacy of common liquid disinfectants against non-spore-forming biological agents in soil matrices. 62
36056613 2022
13
Unravelling the Imaging Conundrum of Rabies. 62
36451958 2022
14
Comparison of laboratory and immune characteristics of the initial and second phase of tick-borne encephalitis. 62
35657098 2022
15
Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. 62
35103548 2022
16
Update on the distribution of Culiseta melanura in regions of Illinois with prior eastern equine encephalitis virus activity. 62
36314679 2022
17
Understanding host responses to equine encephalitis virus infection: implications for therapeutic development. 62
36305549 2022
18
Tick-Talk: Parental online discourse about TBE vaccination. 62
36347719 2022
19
Differential transcriptomic landscapes of multiple organs from SARS-CoV-2 early infected rhesus macaques. 62
35377064 2022
20
Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy 62
36219093 2022
21
Aggressive MOGAD with bilateral corticospinal tract lesions following infection with Jamestown Canyon virus. 62
36403434 2022
22
A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon. 62
35034586 2022
23
Etiologies of Acute Undifferentiated Febrile Illnesses in and near Iquitos from 1993 to 1999 in the Amazon River Basin of Peru. 62
36162442 2022
24
Prevalence of foodborne and zoonotic viral pathogens in raw cow milk samples. 62
36352488 2022
25
Combined assessment of S- and N-specific IL-2 and IL-13 secretion and CD69 neo-expression for discrimination of post-infection and post-vaccination cellular SARS-CoV-2-specific immune response. 62
35690994 2022
26
Genomic Determinants Potentially Associated with Clinical Manifestations of Human-Pathogenic Tick-Borne Flaviviruses. 62
36362200 2022
27
Technical Evaluation of qPCR Multiplex Assays for the Detection of Ixodes ricinus-Borne Pathogens. 62
36363814 2022
28
Serological Surveillance of Zoonotic Pathogens in Rats in Markets in Bogor, Indonesia. 62
36322894 2022
29
Pearls & Oy-sters: Seronegative Eastern Equine Encephalitis in an Immunocompromised Stem Cell Transplant Recipient. 62
36100442 2022
30
RNAi-mediated knockdown of arginine kinase genes leads to high mortality and negatively affect reproduction and blood-feeding behavior of Culex pipiens pallens. 62
36413567 2022
31
Neurological disease suspected to be caused by tick-borne encephalitis virus infection in 6 horses in Switzerland. 62
36093849 2022
32
Arbovirus Antibody Seroprevalence in the Human Population from Cauca, Colombia. 62
36375460 2022
33
PCP consensus protein/peptide alphavirus antigens stimulate broad spectrum neutralizing antibodies. 62
35878658 2022
34
Use of Wild Ungulates as Sentinels of TBEV Circulation in a Naïve Area of the Northwestern Alps, Italy. 62
36431023 2022
35
[Value of metagenomic next-generation sequencing in children with hemophagocytic syndrome with central nervous system involvement]. 62
36398548 2022
36
European College of Equine Internal Medicine consensus statement on equine flaviviridae infections in Europe. 62
36367340 2022
37
Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses. 62
35714271 2022
38
Cross-Reactive Antibodies in Tick-Borne Encephalitis: Case Report and Literature Review. 62
36412838 2022
39
Correction for Goonawardane et al., "Identification of Host Factors Differentially Induced by Clinically Diverse Strains of Tick-Borne Encephalitis Virus". 62
36255279 2022
40
Necroptosis of neuronal cells is related to the neuropathology of tick-borne encephalitis. 62
36064044 2022
41
Tick-borne encephalitis virus capsid protein induces translational shutoff as revealed by its structural-biological analysis. 62
36223838 2022
42
[Tick-Borne Encephalitis (TBE) - Fundamentals]. 62
36303530 2022
43
Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data. 62
36347722 2022
44
[Tick-Borne Encephalitis - Viral Transmission and Considerations for Vaccination]. 62
36303529 2022
45
[Tick-Borne Encephalitis (TBE) - Clinical and Therapeutical Aspects]. 62
36303528 2022
46
Surveillance of tick-borne encephalitis in emerging risk areas in southern Sweden: a retrospective case finding study. 62
36322256 2022
47
Mechanistic insight into the RNA-stimulated ATPase activity of tick-borne encephalitis virus helicase. 62
35987382 2022
48
Tick-borne encephalitis epidemic in Hungary 1951-2021: The story and lessons learned. 62
36205381 2022
49
Tick-Borne Encephalitis Virus RNA Found in Frozen Goat's Milk in a Family Outbreak. 62
36232930 2022
50
Systematic Review and Meta-analysis of Foodborne Tick-Borne Encephalitis, Europe, 1980-2021. 62
36149234 2022

Variations for Viral Encephalitis

Expression for Viral Encephalitis

Search GEO for disease gene expression data for Viral Encephalitis.

Pathways for Viral Encephalitis

Pathways related to Viral Encephalitis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 VEGFA VCAM1 UNC93B1 TNF TLR3 MX1
2
Show member pathways
13.63 VEGFA TNF IL6 IL1B IFNB1 IFNA1
3
Show member pathways
13.55 VEGFA TNF IL6 IL1B IFNB1 IFNA1
4
Show member pathways
13.42 TNF TLR3 IL6 IL1B CXCL10 CD4
5
Show member pathways
13.32 TNF IL6 IL1B CXCL10 CD4 CCR6
6
Show member pathways
13.3 VEGFA VCAM1 TNF MX1 IL6 IL1B
7
Show member pathways
12.91 TNF TLR3 MX1 IL6 IL1B IFNB1
8 12.71 VEGFA IL6 IL1B CXCL10 CCL2
9
Show member pathways
12.65 TNF MX1 IL6 IL1B IFNB1 IFNA1
10
Show member pathways
12.6 TNF IL6 IL1B CD4 CCL2
11
Show member pathways
12.58 TNF TLR3 IL6 IL1B IFNB1 IFNA1
12 12.55 VCAM1 TNF TLR3 IL1B IFNA1 CXCL10
13
Show member pathways
12.49 TLR3 IL6 IL1B IFNB1 IFNA1 CXCL10
14
Show member pathways
12.46 TLR3 IFNB1 IFNA1 CXCL10
15
Show member pathways
12.44 TNF IL6 IL1B IFNB1 CXCL10
16
Show member pathways
12.32 TNF TLR3 IL6 IL1B
17
Show member pathways
12.3 TNF IL6 CXCL10 CCL2
18 12.21 VEGFA TNF TLR3 IL6
19 12.18 IL1B IL6 TNF VEGFA
20
Show member pathways
12.16 TNF IFNB1 CD8A CD4
21 12.05 CCL2 CXCL10 IL1B IL6 MBP TNF
22 12.02 CD4 CD8A IL6 TNF
23 12.01 VEGFA VCAM1 TNF IL6 IL1B CCL2
24
Show member pathways
12 TNF TLR3 IL6 IL1B CD4
25 11.97 VEGFA VCAM1 IL6 CCR6 CCL2
26
Show member pathways
11.92 TLR3 MX1 IFNB1 ACE2
27
Show member pathways
11.9 TLR3 IL6 IL1B CD4
28 11.88 TNF IL1B CD8A CD4 CCR6
29
Show member pathways
11.8 TNF IL1B IFNB1
30 11.77 TLR3 IL6 CD4
31
Show member pathways
11.76 IL1B IL6 TNF VCAM1 VEGFA
32
Show member pathways
11.75 VEGFA IL6 CCL2
33 11.73 IL6 IL1B CD4
34 11.72 TNF IL6 IL1B CCL2
35
Show member pathways
11.69 IL6 IFNB1 CD8A CD4 CCL2 ACE2
36 11.68 IL1B IL6 TNF
37 11.68 IL6 TNF VCAM1
38 11.65 TNF MX1 IFNB1 CCL2 ACE2
39 11.61 VEGFA TNF IL6 IL1B IFNB1 CCL2
40 11.59 CCL2 TNF VCAM1
41 11.59 TNF IL6 IL1B CXCL10 CCL2
42 11.58 TNF IL6 CCL2
43 11.58 CCL2 IL6 TNF VCAM1
44 11.55 TNF IL1B CCL2
45 11.51 TNF IL6 IL1B
46 11.5 TNF IL6 IL1B IFNB1 CD8A CD4
47 11.42 IL1B IFNB1 CXCL10
48 11.38 TNF IL6 IL1B
49 11.34 TNF IL6 IL1B
50 11.28 ACE2 CCL2 IL1B IL6 TNF

GO Terms for Viral Encephalitis

Cellular components related to Viral Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.03 ACE2 CCL2 CXCL10 IFNA1 IFNB1 IL1B
2 external side of plasma membrane GO:0009897 9.93 VCAM1 TNF CXCL10 CD8A CD4 CCR6
3 cell surface GO:0009986 9.53 VEGFA VCAM1 TNF TLR3 MBP CNTNAP2

Biological processes related to Viral Encephalitis according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.55 VEGFA TNF TLR3 MX1 IL6 IL1B
2 inflammatory response GO:0006954 10.32 CCL2 CXCL10 IL1B IL6 TLR3 TNF
3 cytokine-mediated signaling pathway GO:0019221 10.24 IL6 IL1B IFNB1 IFNA1 CCL2
4 cellular response to lipopolysaccharide GO:0071222 10.21 TNF IL6 IL1B CXCL10 CCL2
5 MAPK cascade GO:0000165 10.16 CCL2 IL1B MBP TLR3 TNF
6 positive regulation of interleukin-8 production GO:0032757 10.13 TNF TLR3 IL6 IL1B
7 defense response to virus GO:0051607 10.13 CXCL10 IFNA1 IFNB1 IL6 MX1 TLR3
8 negative regulation of viral genome replication GO:0045071 10.1 TNF MX1 IFNB1
9 response to virus GO:0009615 10.1 TNF TLR3 MX1 IFNB1 CXCL10
10 lipopolysaccharide-mediated signaling pathway GO:0031663 10.09 TNF IL1B CCL2
11 response to exogenous dsRNA GO:0043330 10.08 TLR3 IFNB1 IFNA1
12 cellular response to virus GO:0098586 10.07 TLR3 IL6 IFNB1 IFNA1 CXCL10
13 negative regulation of neurogenesis GO:0050768 10.04 TNF IL6 IL1B
14 positive regulation of glial cell proliferation GO:0060252 10.02 IL1B IL6 TNF
15 positive regulation of chemokine production GO:0032722 10.02 TNF TLR3 IL6 IL1B
16 positive regulation of neuroinflammatory response GO:0150078 9.93 TNF IL6 IL1B
17 positive regulation of interleukin-6 production GO:0032755 9.93 UNC93B1 TNF TLR3 MBP IL6 IL1B
18 positive regulation of fever generation GO:0031622 9.92 IL1B TNF
19 cellular response to interleukin-17 GO:0097398 9.91 IL1B CXCL10
20 toll-like receptor 3 signaling pathway GO:0034138 9.91 TLR3 TNF UNC93B1
21 sequestering of triglyceride GO:0030730 9.89 TNF IL1B
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 TNF IL1B
23 vascular endothelial growth factor production GO:0010573 9.88 TNF IL6 IL1B
24 defense response GO:0006952 9.8 TNF TLR3 MX1 IFNB1 IFNA1 CXCL10
25 humoral immune response GO:0006959 9.73 CCL2 CCR6 IFNA1 IFNB1 IL6 TNF
26 immune response GO:0006955 9.5 TNF TLR3 MBP IL6 IL1B CXCL10

Molecular functions related to Viral Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.47 VEGFA TNF IL6 IL1B IFNB1 IFNA1

Sources for Viral Encephalitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....